This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This study has been completed.
CTI BioPharma
Information provided by:
SCRI Development Innovations, LLC Identifier:
First received: September 12, 2005
Last updated: May 2, 2011
Last verified: May 2011
Additional active agents are needed to further improve the treatment of patients with CLL/SLL. Increasing information exists regarding the activity of arsenic trioxide in other hematologic malignancies. Since arsenic trioxide produces mild to moderate myelosuppression and is not as immunosuppressive as other available agents, it may be an additional treatment option for CLL/SLL. This study will evaluate the feasibility and toxicity of arsenic trioxide in patients with relapsed or refractory CLL/SLL

Condition Intervention Phase
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Drug: Arsenic Trioxide Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial Of Arsenic Trioxide (TRISENOX) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Resource links provided by NLM:

Further study details as provided by SCRI Development Innovations, LLC:

Primary Outcome Measures:
  • Overall response rate

Secondary Outcome Measures:
  • Progression-free survival
  • Toxicity

Estimated Enrollment: 41
Study Start Date: April 2004
Study Completion Date: April 2006
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Upon determination of eligibility, patients will receive:

  • Arsenic Trioxide

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

To be included in this study, you must meet the following criteria:

  • Histologically proven B-cell CLL/SLL.
  • Must have had a minimum of 1 and a maximum of 3 previous systemic regimens
  • Must have progressive CLL/SLL
  • Measurable or evaluable disease
  • ECOG performance status 0, 1, or 2
  • Age > 18 years.
  • Patients with cytopenias caused by bone marrow involvement are eligible
  • All patients must give written informed consent prior to entering this study.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

  • Unstable active infection on the basis of neutropenia
  • Previous severe opportunistic infections
  • Severe immune mediated anemia or thrombocytopenia
  • Serious underlying medical conditions
  • Brain metastases or meningeal involvement
  • History of other neoplasms
  • Significant underlying heart dysfunction
  • Women who are pregnant or

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00193518

United States, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023
Sponsors and Collaborators
SCRI Development Innovations, LLC
CTI BioPharma
Principal Investigator: John D. Hainsworth, MD SCRI Development Innovations, LLC
  More Information

Responsible Party: SCRI Oncology Research Consortium, SCRI Identifier: NCT00193518     History of Changes
Other Study ID Numbers: SCRI LYM 33
Study First Received: September 12, 2005
Last Updated: May 2, 2011

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Arsenic trioxide
Antineoplastic Agents processed this record on June 22, 2017